Medivation Submits NDA For Enzalutamide

Medivation: Interim Analysis For PREVAIL Trial Expected To Occur In 2013

Medivation Q4 Loss Widens

Medivation Q4 12 Earnings Conference Call At 4:30 PM ET

Trade MDVN now with

5/21/2012 8:34 PM ET

Medivation, Inc. (MDVN: Quote) said Monday that it has submitted a New Drug Application to the U.S. Food and Drug Administration for enzalutamide, formerly MDV3100.

The compound has been studied in patients with castration-resistant prostate cancer who have received docetaxel therapy.

The FDA is expected to determine within 60 days whether to accept the filing for review.

Medivation said it has requested Priority Review, a designation given to drugs that offer a significant improvement in treatment or provide treatment where no satisfactory alternative therapy exists.

If a Priority Review is granted, the FDA goal for completing a review is six months.

Click here to receive FREE breaking news email alerts for MEDIVATION INC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 379 Articles Next>>

Editors Pick

Stocks May Give Back Ground In Early Trading - U.S. Commentary

After showing a strong upward move last week, stocks may give back some ground in early trading on Monday. The major index futures are currently pointing to a modestly lower open for the markets, with the Dow futures down by 23 points.

Thailand Cuts 2013 GDP Outlook As Q1 Growth Slows More Than Expected

Thailand lowered its full-year growth outlook after weaker domestic demand and exports weighed on economic activity in the first three months of the year. Gross domestic product expanded 5.3 percent year-on-year in the first quarter of 2013 compared to an upwardly revised 19.1 percent growth in the fourth quarter of 2012, the National Economic and Social Development Board (NESDB) said Monday.

U.K. House Prices Hit Record High: Rightmove

The fifth consecutive monthly increase in the U.K. house prices amid limited supply took average asking prices to a record, a survey by Rightmove showed Monday. House prices hit a record GBP 249,841 in May, as new sellers raised their prices by 2.1 percent from the prior month. Prices were up by the same magniture in April.